MX2015008482A - Composicion vacunal contra el virus dengue. - Google Patents

Composicion vacunal contra el virus dengue.

Info

Publication number
MX2015008482A
MX2015008482A MX2015008482A MX2015008482A MX2015008482A MX 2015008482 A MX2015008482 A MX 2015008482A MX 2015008482 A MX2015008482 A MX 2015008482A MX 2015008482 A MX2015008482 A MX 2015008482A MX 2015008482 A MX2015008482 A MX 2015008482A
Authority
MX
Mexico
Prior art keywords
seq
compositions
dengue virus
oligonucleotide
vaccine composition
Prior art date
Application number
MX2015008482A
Other languages
English (en)
Other versions
MX367424B (es
Inventor
Nieto Gerardo Enrique Guillén
Vazquez Laura Lazo
Cruz Lisset Hermida
González Lázaro Gil
Oliva Alienys Izquierdo
Portal Edith Suzarte
Tirado María Guadalupe Guzmán
Prado Iris Valdés
Arechavaleta Angélica De La Caridad Garciá
Vera Mayling Álvarez
Velazco Jorge Castro
Fernández Lázaro López
Bartutis Rosa Liset Ramírez
Fuentes Yusleidi De La Caridad Pérez
Guevara Olga Lidia Pérez
Fernández Yaremy Romero
López Ernesto Marcos
Original Assignee
Ct Ingenieria Genetica Biotech
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ct Ingenieria Genetica Biotech filed Critical Ct Ingenieria Genetica Biotech
Publication of MX2015008482A publication Critical patent/MX2015008482A/es
Publication of MX367424B publication Critical patent/MX367424B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24121—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24151—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24161—Methods of inactivation or attenuation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Composiciones vacunales que comprenden al menos un antígeno basado en la proteína de la cápsida del virus dengue (VD) y el oligonucleótido identificado como SEQ ID NO. 1; la composición vacunal que comprende una proteína de fusión formada por la cápsida del VD2 y el dominio III de la proteína de la envoltura del mismo serotipo, agregada con el oligonucleótido identificado como SEQ ID NO. 1, genera los mayores niveles de respuesta inmune celular y protección en ratones, al compararla con la generada por formulaciones del mismo antígeno agregado con oligonucleótidos de potencial capacidad adyuvante, reportados antioriomente; la efectividad de las composiciones que comprenden el oligonucleótido de SEQ ID NO.1 fue demostrado en primates no humanos; estas composiciones pueden ser monovalentes, bivalentes y tetravalentes y se combinan en diferentes regímenes de inmunización para inducir respuesta inmune funcional frente a los cuatro serotipos virales.
MX2015008482A 2012-12-27 2013-12-16 Composicion vacunal contra el virus dengue. MX367424B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CUP2012000179A CU24188B1 (es) 2012-12-27 2012-12-27 Composición vacunal contra el virus dengue
PCT/CU2013/000008 WO2014101903A1 (es) 2012-12-27 2013-12-16 Composicion vacunal contra el virus dengue

Publications (2)

Publication Number Publication Date
MX2015008482A true MX2015008482A (es) 2015-09-23
MX367424B MX367424B (es) 2019-08-21

Family

ID=49999644

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015008482A MX367424B (es) 2012-12-27 2013-12-16 Composicion vacunal contra el virus dengue.

Country Status (17)

Country Link
US (1) US9463235B2 (es)
EP (1) EP2939691B1 (es)
JP (1) JP6333290B2 (es)
KR (1) KR102203759B1 (es)
CN (1) CN104936616B (es)
AR (1) AR094238A1 (es)
AU (1) AU2013369626B2 (es)
BR (1) BR112015015138B1 (es)
CA (1) CA2894134C (es)
CU (1) CU24188B1 (es)
ES (1) ES2721921T3 (es)
HK (1) HK1209647A1 (es)
MX (1) MX367424B (es)
MY (1) MY190698A (es)
PH (1) PH12015501446A1 (es)
SG (1) SG11201505170WA (es)
WO (1) WO2014101903A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115089700A (zh) * 2022-05-25 2022-09-23 永州中古生物技术有限公司 一种抗β属冠状病毒的疫苗组合物及其应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU22683A1 (es) * 1997-01-15 2001-07-20 Inst De Medicina Tropical Pedro Kouri Epítopes de la proteína pre-m/m del virus del dengue, péptidos sintéticos, proteínas quiméricas y sus usos
CU23245A1 (es) * 2001-07-16 2007-10-17 Inst De Medicina Tropical Pedr CADENAS QUIMéRICAS CODIFICANTES PARA PROTEINAS INDUCTORAS DE EFECTOS CONTRA VIRUS. PREPARADOS UTILIZANDO PROTEINAS QUIMéRICAS
OA13033A (en) * 2003-02-20 2006-11-10 Ct Nat De Investigaciones Cientificas Attenuated strains of Vibrio cholerae with improved biological safety features in freeze dried form for oral vaccination.
CU23578A1 (es) * 2005-09-16 2010-09-30 Ct Ingenieria Genetica Biotech Proteína de la cápsida del virus dengue inductora de respuesta protectora y composición vacunal
CU23586A1 (es) * 2005-11-22 2010-10-30 Ct Ingenieria Genetica Biotech Métodos y proteínas para el tratamiento profiláctico y/o terapéutico de los cuatro serotipos del virus de dengue y otros flavivirus
CU20080028A6 (es) * 2008-02-29 2011-02-24 Ct Ingenieria Genetica Biotech Compuestos químicos obtenidos in silico para la preparación de composiciones farmacéuticas para atenuar o inhibir la infección por virus dengue y otros flavivirus

Also Published As

Publication number Publication date
SG11201505170WA (en) 2015-08-28
WO2014101903A1 (es) 2014-07-03
CU20120179A7 (es) 2014-08-28
PH12015501446B1 (en) 2015-09-14
EP2939691B1 (en) 2019-02-20
AU2013369626B2 (en) 2017-07-27
JP2016505004A (ja) 2016-02-18
MX367424B (es) 2019-08-21
BR112015015138B1 (pt) 2022-05-17
US9463235B2 (en) 2016-10-11
CU24188B1 (es) 2016-07-29
CA2894134C (en) 2021-04-06
BR112015015138A2 (es) 2017-08-15
CA2894134A1 (en) 2014-07-03
HK1209647A1 (en) 2016-04-08
JP6333290B2 (ja) 2018-05-30
CN104936616B (zh) 2017-06-20
MY190698A (en) 2022-05-11
EP2939691A1 (en) 2015-11-04
CN104936616A (zh) 2015-09-23
PH12015501446A1 (en) 2015-09-14
US20150328304A1 (en) 2015-11-19
ES2721921T3 (es) 2019-08-06
KR102203759B1 (ko) 2021-01-18
KR20150100660A (ko) 2015-09-02
AR094238A1 (es) 2015-07-22

Similar Documents

Publication Publication Date Title
MX2013004159A (es) Proteina vp6 de la capside de norovirus y de rotavirus para el uso como vacuna combinada.
MX2020011717A (es) Composiciones de vacuna que tienen estabilidad e inmunogenicidad mejoradas.
CY1118003T1 (el) Αναπτυξη συστατικων εμβολιου ιου δαγκειου
MX2015008847A (es) Composiciones inmunogenicas de virus de influenza y usos de las mismas.
SG10201903538YA (en) Modified virus-like particles of cmv
WO2009072767A3 (en) A powerful vaccine composition comprising a lipopeptide and poly i:c as an adjuvant
NZ630869A (en) Compositions and methods for dengue virus chimeric constructs in vaccines
MX2008016036A (es) Vacuna viral recombinante.
WO2013054199A3 (en) Cmv antigens and uses thereof
EP2525816A4 (en) PRESENTATION OF TARGETED HETEROLOGOUS ANTIGENS ON CALICIVIRUS VIRAL PSEUDO PARTICLES
NZ618158A (en) Compositions and methods for administration of vaccines against dengue virus
WO2017156511A8 (en) Live attenuated zika virus vaccine
EA201892735A1 (ru) Состав вакцины против hiv
MX2021015972A (es) Vacuna contra la fiebre aftosa.
WO2012118559A3 (en) Tetravalent and mixed head bivalent dengue vaccine
PH12015502666B1 (en) Dengue virus vaccine compositions and methods of use thereof
CU20120057A7 (es) Composición vacunal contra el virus del dengue, kit y plásmido
PH12017501165A1 (en) Dengue virus vaccine compositions and methods of use thereof
EA033027B1 (ru) Ослабленные вакцины от свиного гриппа и способы их получения и применения
BR112012029633A8 (pt) Vetores do parapoxvírus contendo antígeno do vírus da raiva.
WO2014140166A3 (en) Vaccine
PH12015501446B1 (en) Dengue virus vaccine composition
WO2015048785A3 (en) Mosaic conserved region hiv immunogenic polypeptides
MX365656B (es) Nuevas vacunas contra multiples subtipos del virus del dengue.

Legal Events

Date Code Title Description
FG Grant or registration